MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

Search

Mirati Therapeutics Inc

Fermé

SecteurSoins de santé

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés

By Trading Economics

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

-0.05% downside

Sentiment de l'Actualité

By Acuity

50%

50%

162 / 376 Classement par Healthcare

Mirati Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 juil. 2025, 19:37 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

M3-Brigade Shares Fall on Merger With ReserveOne

8 juil. 2025, 23:45 UTC

Market Talk

Gold Edges Lower, Weighed by Higher Treasury Yields -- Market Talk

8 juil. 2025, 23:42 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

8 juil. 2025, 23:27 UTC

Market Talk

Australian REITs Yet to Offer Enough Appeal -- Market Talk

8 juil. 2025, 23:27 UTC

Market Talk

Global Equities Roundup: Market Talk

8 juil. 2025, 23:21 UTC

Market Talk

Summerset Bull Lauds Strong 2Q Sales Volumes -- Market Talk

8 juil. 2025, 23:21 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 juil. 2025, 22:29 UTC

Acquisitions, Fusions, Rachats

Capricorn to Pay A$1.5 Million in Cash and Shares

8 juil. 2025, 22:28 UTC

Acquisitions, Fusions, Rachats

Capricorn Metals Enters Binding Agreement to Buy Claw Gold Project

8 juil. 2025, 21:58 UTC

Market Talk

Kura Sushi Closely Watching U.S. Tariff Negotiations on Asian Goods -- Market Talk

8 juil. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 juil. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 juil. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 juil. 2025, 19:53 UTC

Market Talk

Copper Posts Biggest One-Day Gain Ever to Hit Record on Tariff Chatter -- Market Talk

8 juil. 2025, 19:53 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

8 juil. 2025, 19:45 UTC

Market Talk

Canada Unlikely to Succeed in Bid for Tariff-Free Trade With U.S. -- Market Talk

8 juil. 2025, 19:29 UTC

Market Talk

U.S. Consumer-Credit Growth Slowed in May -- Market Talk

8 juil. 2025, 19:20 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

8 juil. 2025, 19:11 UTC

Market Talk

Bank of Canada's Rate Cuts Deliver Muted Relief Along the Curve -- Market Talk

8 juil. 2025, 19:01 UTC

Market Talk

Oil Futures Gain With Support From Products -- Market Talk

8 juil. 2025, 18:49 UTC

Résultats

Hershey Names New CEO, Continuing Leadership Shuffle. The Stock Falls. -- Barrons.com

8 juil. 2025, 18:41 UTC

Market Talk

Mexico's Inflation Seen Mixed in June -- Market Talk

8 juil. 2025, 18:38 UTC

Market Talk

Gold Falls as Markets Digest Details of Trump Tariffs -- Market Talk

8 juil. 2025, 18:23 UTC

Market Talk

Analysts Anticipate Lower Ethanol Inventories -- Market Talk

8 juil. 2025, 18:10 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

8 juil. 2025, 18:10 UTC

Market Talk

Freeport-McMoRan Jumps on Trump Tariff Plan for Copper Imports -- Market Talk

8 juil. 2025, 17:24 UTC

Market Talk

Election, Dollar Seen as Potential Headwinds for Ibovespa -- Market Talk

8 juil. 2025, 17:06 UTC

Market Talk

KeyCorp and Regional Banks Set for a Catchup -- Market Talk

8 juil. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparaison

Variation de prix

Mirati Therapeutics Inc prévision

Objectif de Prix

By TipRanks

-0.05% baisse

Prévisions sur 12 Mois

Moyen 58.67 USD  -0.05%

Haut 59 USD

Bas 58 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

5 ratings

0

Achat

5

Maintien

0

Vente

Sentiment

By Acuity

162 / 376Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

EBITDA

Bénéfice d'exploitation

$

À Propos Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.